| Bio Roundup: Clinical Trials Paused, New MS Drug, Kallyope’s Cash & More | Frank Vinluan | 03/27/20 | National |
| Oncology Needs Combo Therapies & More Data Analysis, Says Bio-Europe Spring Panel | Sarah de Crescenzo | 03/26/20 | Boston |
| Investors Shaken by Coronavirus Sow Seeds of M&A, Financing Slowdown | Sarah de Crescenzo | 03/23/20 | National |
| Bio Roundup: Coronavirus Diagnostics, Therapeutics, Vaccines & More | Sarah de Crescenzo | 03/20/20 | National |
| As the Commercial Real Estate Market Slumps, Look for a More Tenant-Friendly Future | Editors | 03/19/20 | Boston |
| Bio Roundup: Pandemic Declared, Rubius Restarts, Kymera’s Cash & More | Frank Vinluan | 03/13/20 | National |
| Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More | Sarah de Crescenzo | 03/06/20 | National |
| National Xconomy Awards Now Accepting Nominations for the Best in Biotech | Editors | 03/03/20 | National |
| Bio Roundup: COVID-19 Trials, Esperion’s Approvals, NASH News & More | Frank Vinluan | 02/28/20 | National |
| Lundbeck’s Alder Bio Bet Pays Off With FDA Approval of Migraine Drug | Frank Vinluan | 02/23/20 | National |
| Bio Roundup: Agile Approval, Coronavirus Collabs, Spruce’s $88M & More | Sarah de Crescenzo | 02/21/20 | National |
| Bio Roundup: Goodbye Belviq, LogicBio on Hold, Revolution’s IPO & More | Frank Vinluan | 02/14/20 | National |
| Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks | Frank Vinluan | 02/13/20 | National |
| Two Big Pharma Alliances End in Nixed Deals. Here’s What Happened. | Frank Vinluan | 02/11/20 | National |
| Eli Lilly, Roche Drugs Fail to Move Needle in Genetically Driven Alzheimer’s | Frank Vinluan | 02/10/20 | National |
| Bio Roundup: POTUS on Prices, a16z’s Fund, Aimmune’s Approval & More | Sarah de Crescenzo | 02/07/20 | National |
| Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy | Frank Vinluan | 01/31/20 | San Francisco |
| Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More | Frank Vinluan | 01/31/20 | National |
| BIO Report: More Work Needed to Improve Diversity at Biotech Firms | Sarah de Crescenzo | 01/30/20 | National |
| BioIntelliSense Debuts “Sticker” Sensor to Capture Patient Data Remotely | Sarah de Crescenzo | 01/28/20 | Boulder/Denver |
| Advanced Therapies Are Reshaping Biopharma R&D: KPMG Report | Gareth Macdonald | 01/28/20 | National |
| Life Sciences IPOs Target Collective Raise of More Than $600M This Week | Sarah de Crescenzo | 01/27/20 | National |
| Bio Roundup: Coronavirus Concerns, Sarepta’s CRL, Eye Drug OK’d & More | Sarah de Crescenzo | 01/24/20 | National |
| Bio Roundup: EQRx’s Ambitions, Nektar No Vote, New Frazier Fund & More | Frank Vinluan | 01/17/20 | National |
| FDA Panel Votes Down Nektar Opioid Painkiller, Asks for More Data | Frank Vinluan | 01/14/20 | National |
| Biotech Roundup: Drug Pricing Promises, Bone Disease Data, IPO Plans & More | Sarah de Crescenzo | 01/10/20 | National |
| Bio Roundup: FDA Approvals, Intrexon’s Shift, Melinta Bankruptcy & More | Frank Vinluan | 01/03/20 | National |
| Bio Roundup: Amarin’s Approval, FTC v. Illumina, a $120M Deal & More | Sarah de Crescenzo | 12/20/19 | National |
| ArcherDX Raises $55M to Help Physicians Pick Best Cancer Therapies | Melissa Fassbender | 12/18/19 | Boulder/Denver |
| Bio Roundup: Sarepta’s Approval, Merck M&A, Drug Price Bill & More | Frank Vinluan | 12/13/19 | National |
